Sanofi (SNY) Expected to Announce Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) will likely be announcing its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect Sanofi to post earnings of $0.9330 per share and revenue of $10.8086 billion for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, April 23, 2026 at 7:00 AM ET.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $47.99 on Tuesday. The firm has a market cap of $117.05 billion, a PE ratio of 13.33, a price-to-earnings-growth ratio of 1.20 and a beta of 0.42. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. Sanofi has a 52 week low of $43.32 and a 52 week high of $55.73. The firm’s fifty day moving average is $46.47 and its 200-day moving average is $48.04.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be given a dividend of $2.4225 per share. This represents a dividend yield of 502.0%. This is a positive change from Sanofi’s previous annual dividend of $2.04. The ex-dividend date is Monday, May 4th. Sanofi’s dividend payout ratio is 44.44%.

Institutional Trading of Sanofi

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after acquiring an additional 1,869 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after acquiring an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after purchasing an additional 752 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after purchasing an additional 347 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Sanofi by 36.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after purchasing an additional 875 shares during the period. 14.03% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Monday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Sanofi currently has a consensus rating of “Hold” and a consensus target price of $54.00.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.